The interaction between
tumor cells and the tumor microenvironment (TME) significantly influences
tumorigenesis, so TME-targeted
therapy has attracted widespread attention. We have previously demonstrated that the combination of
dipyridamole,
bestatin, and
dexamethasone (DBD mix, DBDx) is effective against heterogeneous human
pancreatic cancer and
hepatocellular carcinoma in mouse xenograft models. To further expand the therapeutic potential of this
drug combination, herein, we investigated the antitumor efficacy and the underlying mechanism of DBDx and the combination of DBDx and
gefitinib in different mouse xenograft models of human
non-small-cell lung cancer (NSCLC). Three human
cancer cell lines H460, PG, and A431 were used to determine the apoptosis and growth inhibition induced by DBDx,
gefitinib, and their combinations. Changes in
epidermal growth factor receptor (EGFR) signaling pathway-related
proteins were analyzed following treatment using western blotting. In vitro, DBDx strongly inhibited the proliferation of
tumor cells, whereas the combined treatment exhibited a significant synergistic effect. Compared with DBDx, the combination treatment further induced apoptosis and downregulated the expression of molecules associated with EGFR signaling pathway. In vivo, compared with DBDx alone, the combination treatment distinctly inhibited
tumor growth in mouse xenograft models of human NSCLC. Overall, our results indicate that the combination of DBDx and
gefitinib in the treatment of human NSCLC is very promising, which warrants further translational studies.